Business
MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains
Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024 83% Growth in Year-Ove...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains\n\n\n\n\n Q3 2025 Revenue of $11.4 Million, an Increase of 17% over Q3 2024\n \n\n 83% Growth in Year-Over-Year Revenue for International Medical Cannabis\n \n\n International Medical sales now 56% of Total Revenue\n \n\n Increased Cash Balance of $10.6 Million at the end of Q3 2025\n \n\n Operating Expenses Decreased 19% Year-Over-Year\n \n\n Management to Host Conference Call / Webcast on November 13\n \n th\n \n , 2025 at 10:00 am ET\n \n\n\n\n\n TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) --\n \n MediPharm Labs Corp.\n \n (TSX:\n \n\n LABS\n \n\n ) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and nine months ended September 30, 2025.\n \n\n MediPharm delivered another successful quarter of strong year-over-year revenue growth in the three months ended September 30, 2025 (\"Q3 2025\"), advancing the Company's international medical cannabis strategy to increase revenue, while reducing costs and increasing the Company's cash balance. Continued international momentum, disciplined cost management and a solid balance sheet highlight the Company's commitment to scaling responsibly, to drive sustainable growth and long-term value creation.\n \n (2)\n \n\n\n \"Our third quarter results reflect the strength of our international strategy, and the resilience of our differentiated business model\" said David Pidduck, CEO of MediPharm Labs. \"MediPharm is uniquely positioned to serve the most complex and highest value medical cannabis markets worldwide with a range of direct to patient, partnership and distribution pathways.\"\n \n (2)\n \n\n\n Greg Hunter, CFO of MediPharm Labs, added, \"The third quarter continued to show our commercial strategy is working, with Q3 2025 revenue growth of 17% and year-to-date revenue growth of 14%. We maintained our disciplined approach to expense and cash management, reducing operating expenses by 19% versus prior year and 35% versus prior quarter, while increasing our cash balance to $10.6 million at the end of Q3 2025. As we move forward, management remains focused and relentless in driving further revenue g...